MAF and metastatic neoplasm: For M2TS, additional studies in primary or metastatic tumors similarly were consistent with immunosuppressive or pro-tumoral functions (MRC1 [23,29,30], MS4A4A [31,32], CD36 [23,33,34], CCL13 [35], CCL18 [29,36,37], CCL23 [38,39], SLC38A6, FGL2 [40,41], FN1 [42,43], MAF [30]).